| Autor: |
Guadagni S; Departments of aApplied Clinical Sciences and Biotechnology bLife, Health and Environmental Sciences, University of L'Aquila cDepartment of Pathology, S. Salvatore Hospital, L'Aquila dDepartment of Oncology and Hematology, Azienda Ospedaliera 'Ospedali Riuniti Marche Nord', Pesaro eIstituto Tumori Milano, Milano fDepartment of Surgical Sciences, University of Verona, Verona, Italy., Fiorentini G, Clementi M, Palumbo G, Masedu F, Deraco M, De Manzoni G, Chiominto A, Valenti M, Pellegrini C |
| Jazyk: |
angličtina |
| Zdroj: |
Melanoma research [Melanoma Res] 2017 Oct; Vol. 27 (5), pp. 439-447. |
| DOI: |
10.1097/CMR.0000000000000367 |
| Abstrakt: |
Approximately 25% of melanoma patients with locoregional metastases are nonresponsive to new molecular target therapy and immunotherapy. When metastases are located in the pelvis, melphalan hypoxic perfusion can be an optional treatment. Because methylation of MGMT promoter increases the efficacy of alkylating agents, studies on melanoma outcome of patients treated with melphalan regional chemotherapy should consider this epigenetic change. This study aims to evaluate whether the survival of stage III melanoma patients treated with melphalan regional chemotherapy may be correlated with MGMT methylation status. The metastatic tissues of 27 stage III melanoma patients with locoregional metastases located in the pelvis subjected to melphalan hypoxic pelvic perfusion were examined. The methylation status of the MGMT promoter was investigated by MS-MLPA probes analysis and the presence of the BRAF V600E mutation was analyzed by CAST-PCR. The median survival times were estimated using the Kaplan-Meier curves and were stratified according to the clinicopathological characteristics of patients and lesions. The overall median survival time was 17 months. The 1-year, 3-year, and 5-year survival rates were 66.7, 18.5, and 7.4%, respectively. Disease stage, burden, and percentage of MGMT methylation significantly affected survival. We estimated an MGMT promoter methylation cut-off of at least 14%, which was significantly associated with a longer survival after melphalan regional chemotherapy. Our data suggest that MGMT promoter methylation could be an important factor in determining which melanoma patients should receive melphalan regional chemotherapy, but its prognostic significance in the routine clinical setting needs to be clarified in a larger study. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
